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Tumors are spatially heterogeneous, with regions of relative hypoxia and normoxia. The tumor microenvironment
is an important determinant of both tumor growth and response to a variety of cytotoxic and targeted therapies. In
the tumor microenvironment, reactive oxygen species and nitric oxide (NO) are important mediators of the level of
expression of many transcription factors and signaling cascades that affect tumor growth and responses to
therapy. The primary objective of this review is to explore and discuss the seemingly dichotomous actions of NO in
cancer biology as both a tumor promoter and suppressor with an emphasis on understanding the role of
persistently low NO concentrations or hyponitroxia as a key mediator in tumor progression. This review will also
discuss the potential role of hyponitroxia as a novel therapeutic target to treat cancer and outline an approach that
provides new opportunities for pharmacological intervention.
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This review highlights the function of hyponitroxia as a proneoplastic
effector, summarizes therapeutic strategies to increase intratumoral
nitric oxide (NO) to mitigate, at least in part, the effect of
hyponitroxia on angiogenesis and malignant progression, and
makes the case for hyponitroxia a high-priority target in cancer
therapy that may be as, if not more, important than hypoxia.
As in tumors, NO also plays an important role in normal tissues.
Under physiological conditions, low levels of NO are produced from
L-arginine by constitutively expressed NO synthase in neuronal cells
(nNOS, also known as NOS1) and endothelial cells (eNOS or
NOS3) [1], which contribute to the regulation of normal
physiological processes through cell signaling (Figure 1). Higher
levels of NO are produced by an inducible nitric oxide synthase
(iNOS or NOS2) [1]. NO can stimulate pathways resulting in either
cell growth or cell death, depending on the relative level of NO and a
variety of associated factors [2].
The Hyponitroxia and Hypoxia Axis
In tumors, hyponitroxia is relative rather than absolute: low levels of
NO (b100 nM) [3] are produced by three NOS enzymes described
above [4]) and associated with the oxidative burst of macrophages. At
the low concentrations of NO found in tumors, NO mediates redox
signaling pathways linked to the proangiogenic activities of vascular
endothelial growth factor and inhibition of thrombospondin 1 [5],
promoting malignant conversion, tumor progression [6], andresistance to therapy in multiple cancers including prostate [7],
colonic, lung [8], and mammary adenocarcinomas [8,9]. Other
candidate oncogenic functions of NO include cell proliferation,
invasion and metastasis, and stem cell renewal [3]. Hyponitroxia thus
represents a modified form of hormesis [10], a dose-response model
characterized by a beneficial effect at low doses and a detrimental effect
at high doses. NO also exerts a direct effect on responses to hypoxia
through changes in expression of hypoxia inducible factor, alpha
subunit (HIF-1α). Mimicking and attenuating hypoxia [11], NO
drives HIF-1α signaling, by inhibition of prolyl hydroxylase 2 [12],
resulting in a more aggressive and resistant phenotype (Figure 2).
Hypoxia catalyzes the oncogenicity of NO: in addition to L-arginine,
molecular oxygen is an essential substrate for the activity of NOSs, and
exposure to low-oxygen tension limits endogenous NO production by
these enzymes [13,14].However, in the absence of complete anoxia, a rare
state even in tumors, NO synthesis is only inhibited rather than abrogated
[14], resulting in the constitutive induction of the enzyme guanyl cyclase
(GC) [15] and the accumulation of its downstream mitogenic effector
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their inactivation, has also been proposed as a mechanism by which NO
can block apoptosis and result in tumorigenesis [16]. In addition, hypoxia
also redirects macrophage L-arginine metabolism from NOS to arginase
[17], an enzyme that converts L-arginine to urea, leading to decreased
arginine availability as a substrate for NO production.
Thus, as an inactivating mechanism for endogenous NO
production, hypoxia acts as a protumorigenic stimulus, potentiating
the destructive potential of NO [18], separate from its effects on
nuclear factor kappa-light-chain-enhancer of activated B cells
(NF-κB) [19] and HIF-dependent transcriptional pathways.
However, the reverse is true as well: hyponitroxia exacerbates
hypoxia through alterations in blood flow and oxygen consumption
through NO mitochondria-mediated pathways [20,21]. Therefore,
hypoxia and hyponitroxia are closely related and can affect a variety of
downstream targets—either simultaneously or sequentially.
NO-Mediated Effects
In the past two decades or so, NO has been implicated in a wide
array of potential effects on cancer suppression and progression. It is
now generally agreed that NO has a highly context-dependent dose–
response stimulation-inhibition relationship with cytotoxicity at high
doses and mitogenicity at low doses [22]. Thus, NO has the ability to
both promote and suppress cancer.
However, these binary either/or descriptions are an oversimplifi-
cation. At low constitutive levels induced by hypoxia in tumors, NO
levels are optimal for the mediation of aberrant, proliferative
signaling. In contrast, levels either above or below this optimal
range can have the opposite effect and activate signal transduction
pathways that contribute to/result in growth inhibition or cell death.
The Threshold Dose and Cytotoxicity
NO is a radical with a free electron capable of interacting with reactive
oxygen species (ROS) such as the superoxide anion to form a variety
of highly reactive nitrogen oxides (NOx). The term nitrosative stress
refers to the formation of NOx compounds such as peroxynitrite
(ONOO−), nitrogen dioxide (NO2), and dinitrogen trioxide (N2O3)
that are responsible for cytotoxic nitration and oxidation re-
actions [23] leading to apoptosis and cell death. In particular, the
formation of peroxynitrite is a first-order reaction [23] dependent on
the concentrations of NO and the superoxide anion and, therefore,Figure 1. The nitrate-nitrite-NO pathway. NO is generated from the pr
Under these conditions, NO is oxidized to nitrite and nitrate. Under hy
to form NO [2].on oxygen tension, because in the presence of hypoxia, both NO and
ROS such as the superoxide anion will be less prevalent.
Xie et al [24] demonstrated that transfection of murine K-1735
melanoma cells with inducible NOS leading to the generation of
high levels of NO resulted in suppression of tumorigenicity and
metastasis. The cytotoxicity of higher concentrations of NO is
consistent with the assumption that the toxic effect becomes apparent
above a threshold dose of NOx. This balance between mitogenic and
toxic effects of NO in tumor cells is potentially attributable to an
increased susceptibility to free radical damage due to severe
impairment of the antioxidant defense system [25] compared with
healthy cells.
In cancer cells, reactive oxygen/nitrogen species “reprogram” the
cellular metabolism toward a dependence on glucose use, termed the
Warburg effect, a signature of virtually all tumors and the basis of
fluorodeoxyglucose positron emission tomography imaging, to
support anabolic proliferation. The fact that this core feature of
tumors, metabolic reprogramming, is dependent on redox signaling
implies that ROS/reactive nitrogen species (RNS) levels are higher in
tumors than in healthy tissue, resulting in a differential sensitivity to
oxidant stress [26]. Indeed, the presence of high levels of ROS in
tumors has been linked with cell cycle arrest and apoptosis [27].
However, NOx cytotoxicity may not require superelevated doses
but rather approximate “normalization” to physiological levels [27],
because shifts in a particular direction can have important
consequences. For example, Frederiksen et al. demonstrated that
NO enrichment through low concentrations of the NO mimetics
glyceryl trinitrate (GTN) and isosorbide dinitrate attenuated hypoxia-
induced resistance to doxorubicin in prostate cancer mouse models.
At the other end of the spectrum, Kashiwagi and Jain [28]
described radiosensitization in glioma xenografts through the
normalizing effects of NOS inhibition on the tumor vasculature.
The cytotoxicity of NO below a certain threshold is consistent with
the assumption that lower concentrations of NO reduce signal
transduction below a physiological baseline, leading to a loss of the
aberrant induction of proangiogenic [5] signaling [29] networks that
promote malignant progression (Figure 3).
This emerging background of conflicting preclinical evidence that
both anti-NO–centered and pro-NO–centered therapeutic strategies
are therapeutically effective has resulted in the initiation of human
clinical trials with both NO donors and NO inhibitors such asecursor L-arginine by the enzyme NOS under normoxic conditions.
poxia, nitrite is reduced by a variety of NOS-independent processes
Figure 2. The relationship between nitric oxide and hypoxia.
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push the tumor out of its “hormetic comfort zone.”
NO and Epigenetics
As an operational definition, epigenetics comprises heritable alterations
in gene expression not due to changes in the underlyingDNA sequence.
These epigenetic alterations may involve changes in DNA methylation
patterns, altered mRNA expression, and modifications of the histones
around which the DNA is wrapped. NO has been shown to be an
epigenetic factor on the basis of its ability to influence DNA
methylation, microRNA and histone modification in normal [30] as
well as tumor tissues [31], acting directly [32] or through induction of
NOSs [33]. As a consequence of these mechanisms, therapies that result
in global epigenetic changes in the tumor microenvironment or
ecosystem [34] due to selective delivery or inhibition of NO may alter
the tumor phenotype in such a way that it becomes sensitized or
resensitized to subsequent chemotherapy, leading to improved overall
survival [31,32,35]. Furthermore, it is possible that some epigenetic
effects (e.g., DNA methylation, histone modifications, and micro-
RNAs), might have immunomodulatory effects and could potentially
affect immune cell and cytokine function in the tumor microenviron-
ment in such a way as to facilitate antitumor immune responses.
NO and p53
In response to DNA damage, the p53 tumor suppressor protein
activates checkpoint-mediated G1/S arrest or apoptosis to prevent
proliferation of cells with a damaged genome. p53 transcriptionallyFigure 3. Hyponitroxia and the tumor response: How low can you go
tumor growth, whereas subphysiologic but detectable levels promo
signaling cascades.activates downstream genes such as p21, which bind to and inhibit
several cyclin dependent kinase complexes. p53 is also implicated in
the induction of cellular senescence, also through p21 gene activation.
An increase in NO levels may lead to tumor senescence, characterized
by p53 activation, through p53 nuclear retention [35] and the
secretion of proinflammatory cytokines such as Interleukin 6 (IL-6)
and IL-8, which stimulate the immune system.
The modulation of senescence through selective NO delivery to
tumors may improve cancer outcomes through a reduction in
toxicity-related side effects and stimulation of immune activity,
limiting the growth of tumors that have bypassed many major tumor
suppressor blocks [36–38].
NO and the Immune Response
A large number of studies have implicated NO as having an important
role in immune function [39]. As initially described, macrophages
were shown to produce NO in response to infection, which functions
directly to kill or suppress replication of infectious pathogens. It was
subsequently determined that other immune cells including
neutrophils, eosinophils, nonhematopoietic cells, and even certain
subsets of dendritic cells express NO, further supporting the notion
that NO may have important modulatory actions on the immune
system. The role of NO in the immune system is complex, and effects
of NO on immune function can be enhancing or suppressing,
depending on the level of exposure and the context in which it is
available. For example, studies have shown that NO suppresses? Physiologic or very low concentrations of intratumoral NO inhibit
te tumor growth through induction of angiogenesis and action on
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factor forkhead box P3 (Foxp3+) regulatory T cell (Treg) and drives
differentiation toward the T helper cells 1 (Th1) lineage. In addition,
in the presence of NO, transforming growth factor β–driven Th17
differentiation can predominate over Th1 as NO competes with IL-6
to refine the direction of differentiation [40]. Thus, there is important
relevance in understanding the immunologic role that NO may play
as a potential therapeutic target for the treatment of inflammatory
disease or in the context of cancer with respect to the tumor
microenvironment.
Mechanisms by which NO can impact immune function include
changes in signaling pathways and transcription factors that,
understandably so, can be similar to those that mediate antigen-
dependent differentiation of T cells. NO can effect modulation of
signaling cascades like mitogen-activated protein kinase, phosphoi-
nositide 3-kinase, and janus kinase/signal transducer and activator of
transcription pathways [41]. In addition to regulating p53 activity
described above, NO can mediate a variety of control mechanisms
on NF-κB including inhibition of DNA binding of NK-κB through
S-nitrosylation of the p50 subunit, activating p21 Ras, and
controlling inhibitor of kappa B (I-kB) or I-kB kinase [42,43].
The expression of such key molecules that control the fate of
immune cells including B-cell lymphoma 2, B-cell lymphoma-extra
large, and BCL2-associated X protein can also be impacted by
exposure to NO [44].
As above, epigenetic effects may have modulatory effects on the
immune system. Several lines of evidence support this concept: T and
B cell differentiation are influenced by epigenetic mechanisms as well
as the transcriptional control of Foxp3 gene expression [45,46], which
plays a key role in CD4+ T cell differentiation into Treg cells [47].
Thus, these events can have broad impact on the survival and activity
of T cells, as well as other immune cells.
Another immune-related mechanism relevant for discussion can
be found in the context of cancer where elevated NO levels have
been shown to have antitumor activity. NO can sensitize tumor cells
to immune-mediated killing through Fas-, tumor necrosis factor
(TNF)-related apoptosis-inducing ligand, and TNF-α–dependent
mechanisms. The mechanism by which NO increases Fas sensitivity
is due to inhibition of NF-κB and Yin Yang 1 that allows for increased
levels of death-inducing Fas on the surface of tumor cells [48].
Reduction of the transcriptional repressor Yin Yang 1 also allows for
increased expression of Trail on tumors and hence enhanced sensitivity
to Trail-mediated apoptosis [49]. Because many tumors have
mechanisms to circumvent apoptosis, elevated levels of NO could
theoretically resensitize tumors to the induction of apoptosis.
Nitroglycerin
NTG, or GTN, is an approved antianginal NO-donating nitrate ester
[50] repurposed for evaluation as a single agent and chemosensitizer
in late-stage cancer clinical trials.
Monotherapy
In a phase II study, patients with prostate cancer who had failed
primary therapy were treated with a low dose of sustained delivery
GTN resulting in a significant decrease in prostate-specific antigen.
The authors suggested that, although low-dose NO had no direct
cytotoxic effect, NO decreased the emergence of a more malignant
phenotype, including invasion and metastases [2], potentially by
“normalizing” or “boosting” NO to physiological ranges. Analternative hypothesis supporting these observations is that prolonged
and sustained delivery of NO paradoxically resulted in inhibition of
NO signaling through tachyphylaxis due to feedback inhibition of
GC [2]. The latter possibility suggests itself as a consequence of the
observations of Sonveaux et al., who have demonstrated that ionizing
radiation activates proangiogenic signaling cascades through up-
regulation of NOS in endothelial cells and NO production in the
tumor vascular bed [51]. These studies suggest that it may be
necessary to exceed a minimum threshold dose of NO before a
switchlike response from a tumor stimulant to cytotoxicant is elicited.
Chemosensitization
The effect of NO supplementation on the efficacy of chemother-
apy was studied in a double-blind phase II randomized study of 120
patients with stage IIIB/IV non small cell lung cancer (NSCLC) [52],
randomly assigned to a hybrid regimen of alternating courses of
vinorelbine and cisplatin with either an NTG patch or placebo. Both
time to disease progression and overall response rate were found to be
significantly increased in the NTG arm. This marked effect of NO
could be attributed to a normalization of NO levels from low to a
normal physiological range in the tumor or, alternatively, an effect on
GC and cyclic guanosine monophosphate production through
feedback inhibition. Both scenarios would lead to disruption of the
proangiogenic redox signaling circuitry. Although the investigators on
the study mention a phase III trial, an extended search in PubMed
and clinical trial listings found two recruiting phase II studies in non–
small cell lung cancer and prostate cancer.
N-Nitro-L-Arginine
The reliance of tumors [53] on NO-mediated mechanisms of
progression and metastasis prompted an evaluation of L-NNA, a
competitive inhibitor of NOS with selectivity for the neuronal and
endothelial isoforms of the enzyme, in a phase 1 study of patients with
NSCLC. Serial assessment with dynamic contrast-enhanced com-
puted tomography demonstrated decreased vascular blood volume by
40%, an effect that was sustained 24 hours posttreatment [54]. It is
not known whether this decrease in blood volume was associated with
tumor shrinkage.
Extrapolation from these data suggests that tumors can only thrive
within a hyponitroxic “comfort zone” of signaling cell strength;
attenuation below and elevation above this level result in cell death or
senescence [55]. Inhibition of NO synthesis has catastrophic effects
on the tumor vasculature, which can be attributed to the involvement
of NO in tumor angiogenesis and the maintenance of vasodilator tone
of tumor blood vessels.
The sustained disruption of the tumor vasculature was preceded
by a mild transient increase in systemic blood pressure; this
discrepancy was attributed to a differential dependence on NO in
healthy and cancerous tissues [56]. Unlike the cardiovascular system,
which is subjected to tightly regulated homeostatic controls [56], the
patency of vessels within tumors is largely regulated by increased
expression of NO. Therefore, the consequence of NO inhibition was
a conversion of net vasodilation to vasoconstriction, with a collapse
of tumor blood flow.
RRx-001
RRx-001 [57] is an aerospace industry–derived small-molecule redox
regulator with NO-donating properties that has recently completed a
phase I clinical trial in patients with a variety of solid tumors. In
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action that involves selective and specific modification of hemoglobin
in a subpopulation of RBCs, resulting in a catalytic, hypoxia-driven
overproduction of NO [58]. This, in turn, leads to excess NOx, free
radicals (RNS), diffusible metabolites, chemokines, and cytokines, all
of which are preferentially toxic and selectively target the tumor
microenvironment in a manner that mimics, with NOx instead of
oxygen, the “respiratory burst” associated with intracellular killing of
bacteria by phagocytes. The basis for therapeutic selectivity is
controlled release of these endothelial cytotoxins under conditions of
hypoxia and free radical overload—stress conditions that are unique
to the aberrant tumor microvasculature.
RRx-001 acts as an NO donor that irreversibly binds to and
allosterically modifies its target, the β Cys93 residue on deoxygenated
hemoglobin [59]. Although deoxygenated hemoglobin can function
as a nitrite reductase converting the inorganic anion nitrite into NO
under hypoxic conditions, the binding of RRx-001 to this residue
greatly amplifies and accelerates this catalytic reaction [58]. This in
situ generation of ROS/RNS under hypoxia shifts the biocharacter of
the tumor microenvironment from habitable to inhabitable, whereas
the ultrashort lifetime of ROS and RNS confines their activity to the
tumor, sparing normal tissues from toxicity.
Therefore, RRx-001 can amplify oxidative and nitrosative stress
under low-oxygen conditions that are specific to the tumor
microenvironment. In addition, RRx-001 selectively depletes the
antioxidant glutathione (reduced glutathione), resulting in a
systemic increase of ROS [59] that can also exert an antitumor
effect through the exquisite sensitivity of tumors to perturbations in
oxidative stress [55,57].
Preliminary data suggest that RRx-001 acts in a stress-response
pathway, presumably through NO release, that promotes activation
of the transcription factor nuclear factor (erythroid-derived 2)-like 2
and the tumor suppressors p53 and p21, supporting the emerging
idea that RRx-001 leads to the onset of replicative senescence,
resulting in cell cycle arrest or apoptosis in addition to other
mechanisms of cell death. In a phase I trial, many patients had stable
disease, with the median overall survival of 16.8 months, suggesting a
possible survival advantage (RadioRx, 2013). In addition, three
patients subsequently responded to chemotherapy regimens to which
they had previously failed, suggesting that the prior RRx-001
treatment had resulted in resensitization. We have hypothesized
that RRx-001 induced high tumor levels of NO/RNS that resulted in
epigenetic changes in the patients' tumors that made them more
sensitive to subsequent therapies. This is an active area of ongoing
investigation.
Conclusions and Future Directions
NO has only recently been recognized as a potentially useful
target for treating cancer. A recent search of clinical trials listed on
ClinicalTrials.gov revealed more than a hundred studies involving
cancer and hypoxia. By contrast, there are less than 10 involving
cancer and NO.
Rather than characterizing hyponitroxia as an accomplice to
hypoxia, it might be more appropriate to describe the relationship of
ROS and NO in terms of codependency because they interact
cooperatively and reciprocally to mutually modulate biologic effects.
Like an endocrine feedback system, the ROS/RNS axis operates
through dose-responsive facilitative and inhibitory interactions. For
example, NOS is inhibited under hypoxia and stimulated under oxicconditions, whereas NO interferes with mitochondrial respiration
and increases oxygen availability. In addition, NO and superoxide
anion scavenge each other [60]. In this tightly coupled control,
modulation of one element of the axis should induce a concomitant
change of the other in the same direction.
It is important to point out that tumors are spatially heterogeneous
with areas of hypoxia and normoxia, which can be stable or transient.
This heterogeneity, with associated regions of hypoxia, is an
important contributor to resistance of many tumors to therapy. It
is anticipated that NO/RNS levels are also heterogeneous in tumors.
It will be important to study the effect of NO/NRS-generating agents
on this heterogeneity, which may be particularly relevant to
understanding how modulation of NO levels within tumors may
affect tumor responses when these agents are given concurrently or
sequentially with other therapies.
In the literature, the response to NO has been described as biphasic
[61], with homeostasis at low doses and toxicity at higher doses. In
terms of tumors, NO responses may more closely follow a triphasic
response, with cytotoxicity at physiological (and higher) doses,
maintenance of homeostasis at hyponitroxic doses, and cytotoxicity
again at even lower doses. The exploitation and modulation of
hyponitroxia are potentially promising and exciting anticancer
strategies, especially because direct approaches to improve the
oxygenation of tumors with hyperbaric oxygen or a variety of
methods of enhanced delivery have by and large been unsuccessful
[62]. By contrast, hyponitroxia may be a more accessible target
than hypoxia, indirectly resulting in an alteration of the oxygen
status of the tumor.
Because the steady-state concentration of NOx conducive to
invasion, angiogenesis, and metastasis is confined to a narrow
hyponitroxic range, any significant perturbation in the fully coupled
ROS/RNS axis in either direction, below or above, is likely to result in
antitumor responses, especially in combination with chemotherapy or
radiation therapy as mentioned above.
In summary, there is a need for discovery identification and study
of new agents that target hyponitroxia and exert their anticancer
activity through modulation of intratumoral NO, thereby tipping the
balance from tumor cell survival to cell death and senescence. In
addition, further research into new imaging modalities that can
capture the effects of NO on tumors will be required [63]. Research
into the use of NO/RNS modulation for purposes of signal
amplification and attenuation with GTN (and other organic nitrates),
RRx-001, and L-NNA may help to elucidate the molecular
mechanism of action of these agents to enable optimization of their
use both as single agents and in combination with other therapies on
the basis of a better understanding of the underlying biology of
hyponitroxia and facilitate the clinical development of new treatment
options on the basis of this innovative approach.References
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